Broadly neutralizing antibodies (bNAbs) are rarely elicited by current human immunodeficiency virus type 1 (HIV-1) vaccine designs, but the presence of bNAbs in naturally infected individuals may be associated with high plasma viral loads, suggesting that the magnitude, duration, and diversity of viral exposure may contribute to the development of bNAbs. Here, we report the isolation and characterization of a panel of human monoclonal antibodies (mAbs) from two subjects who developed broadly neutralizing autologous antibody responses during HIV-1 infection. In both subjects, we identified collections of mAbs that exhibited specificity only to a few autologous envelopes (Envs), with some mAbs exhibiting specificity only to a subset of Envs w...
Broadly neutralizing antibodies against highly variable viral pathogens are much sought after to tre...
A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of ex...
Broadly neutralizing antibodies are considered an important part of a successful HIV vaccine. A bett...
Broadly neutralizing antibodies (bNAbs) are rarely elicited by current human immunodeficiency virus ...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
Developing HIV-1 vaccines that trigger broadly neutralizing antibodies (bnAbs) is a priority as bnAb...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
BACKGROUND: The isolation of human monoclonal antibodies (mAbs) that neutralize a broad spectrum of ...
The isolation of human monoclonal antibodies (mAbs) that neutralize a broad spectrum of primary HIV-...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
Abstract A large array of broadly neutralizing antibodies (bnAbs) against HIV have been isolated and...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
Some HIV-1-infected patients develop broad and potent HIV-1 neutralizing antibodies (bNAbs) that whe...
Plasma from a small subset of subjects chronically infected with HIV-1 shows remarkable magnitude an...
Thesis (Ph.D.)--University of Washington, 2014Eliciting a neutralizing antibody (Nab) response that ...
Broadly neutralizing antibodies against highly variable viral pathogens are much sought after to tre...
A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of ex...
Broadly neutralizing antibodies are considered an important part of a successful HIV vaccine. A bett...
Broadly neutralizing antibodies (bNAbs) are rarely elicited by current human immunodeficiency virus ...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
Developing HIV-1 vaccines that trigger broadly neutralizing antibodies (bnAbs) is a priority as bnAb...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
BACKGROUND: The isolation of human monoclonal antibodies (mAbs) that neutralize a broad spectrum of ...
The isolation of human monoclonal antibodies (mAbs) that neutralize a broad spectrum of primary HIV-...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
Abstract A large array of broadly neutralizing antibodies (bnAbs) against HIV have been isolated and...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
Some HIV-1-infected patients develop broad and potent HIV-1 neutralizing antibodies (bNAbs) that whe...
Plasma from a small subset of subjects chronically infected with HIV-1 shows remarkable magnitude an...
Thesis (Ph.D.)--University of Washington, 2014Eliciting a neutralizing antibody (Nab) response that ...
Broadly neutralizing antibodies against highly variable viral pathogens are much sought after to tre...
A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of ex...
Broadly neutralizing antibodies are considered an important part of a successful HIV vaccine. A bett...